Orlando, FL 7/9/12 (StreetBeat) -- Questcor (Nasdaq:QCOR) popped 8.3% in early trading Monday, near 54.40, after it released preliminary June sales of its lone drug, Acthar.
The company estimated it sold 400-410 paid prescriptions for the leading indication, multiple sclerosis, up at least 50% from June 2011. Anti-nephrotic syndrome prescriptions, which Questcor started actively marketing last year, jumped more than fivefold to 115-120. There were also three prescriptions filled for a rheumatology condition called dermatomyositis/polymyositis, for which Questcor announced commercialization plans last month.
The move brought Questcor's shares to an all-time high after they previously topped out at 54.30 on June 26.
Questcor, a longtime member of the IBD 50 rankings of top stocks, is currently No. 2.
Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail firstname.lastname@example.org or call (662) 392-0740 for pricing and scheduling.